Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC9V and High-dose Quadrivalent Influenza Vaccine Co-administration in Adults Aged 65 Years or Older
NCT06134804Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Feb 2024
- Modality
- Split/Subunit Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of ExPEC9V in invasive extraintestinal pathogenic Escherichia coli disease (IED), sponsored by Janssen Pharmaceutical. Started Oct 2023; status: completed.
02
Drugs
ExPEC9V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)
Beyond the preview
Go deeper on NCT06134804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134804.